Search
Dithioerythritol
go.drugbank.com/drugs/DB01692ExperimentalA compound that, along with its isomer, Cleland's reagent (dithiothreitol), is used for the protection of sulfhydryl groups against oxidation to disulfides and for the reduction of disulfides to sulfhydryl
Categories: Compounds used in a research, industrial, or household settingAICA ribonucleotide
go.drugbank.com/drugs/DB01700InvestigationalThe drug was first used in the 1980s as a method to preserve blood flow to the heart during surgery and is currently of interest as a potential treatment for diabetes by increasing the metabolic activity
Synonyms: 5-amino-1-(5-phospho-D-ribosyl)imidazole-4-carboxamide2-phospho-D-glyceric acid
go.drugbank.com/drugs/DB01709ExperimentalA 2-phosphoglyceric acid in which the glyceric acid moiety has D (R) configuration.
Synonyms: 2-phospho-D-glycerate, D-glycerate 2-phosphateLemborexant
go.drugbank.com/drugs/DB11951ApprovedInvestigationalbeginning of a new wave of treatment options for patients suffering from insomnia. … Lemborexant is a novel dual orexin receptor antagonist used in the treatment of insomnia characterized by difficulties with sleep onset and/or sleep maintenance.
Avatrombopag
go.drugbank.com/drugs/DB11995ApprovedInvestigational[A33095] Thrombocytopenia is a common complication in patients suffering from chronic liver disease, occurring as a result of liver disease or a consequence of interferon-based antiviral therapy. … [L2927] _Doptelet_ (Avatrombopag) is the first orally administered treatment option for patients with chronic liver disease, allowing a large population of patients to avoid a platelet transfusion before
Alpelisib
go.drugbank.com/drugs/DB12015ApprovedInvestigationalIt works by selectively inhibiting class I PI3K p110α [A179203], which is the catalytic subunit of PI3K, a lipid kinase that plays a role in various biological processes, including proliferation, survival … Alpelisib is a phosphatidylinositol 3-kinase (PI3K) inhibitor with potent antitumor activity.
Categories: Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic IndexLetermovir
go.drugbank.com/drugs/DB12070ApprovedInvestigational[L1021] It is the first of a new class of CMV anti-infectives called DNA terminase complex inhibitors.[A31290] Letermovir has recieved both priority and orphan drug status from the FDA.
Landiolol
go.drugbank.com/drugs/DB12212ApprovedInvestigational[A264733] Compared to other beta-blockers, landiolol possesses unique pharmacodynamic and pharmacokinetic properties, in that it has a rapid onset and short duration of action, and has a greater affinity … Landiolol is a rapid-acting beta (β)-1 adrenergic receptor blocker that blocks the positive chronotropic effect of the beta-1 selective agonist norepinephrine.
Siponimod
go.drugbank.com/drugs/DB12371ApprovedInvestigational[L12171] This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA … Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS).
Categories: Cytochrome P-450 CYP2C9 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic IndexOmadacycline
go.drugbank.com/drugs/DB12455ApprovedInvestigationalOmadacycline represents a significant advance over the well-known tetracycline family, and has been shown to be highly effective in animal models at treating increasingly problematic, clinically prevalent